Seres Therapeutics (NASDAQ: MCRB)
Seres Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Seres Therapeutics Company Info
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
News & Analysis
Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday
The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.
Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday
Positive news for the company's lead therapy and improving financials helped push the stock.
Why Seres Therapeutics Stock Is Soaring Today
The company completed its target enrollment in a pivotal clinical study.
Why Seres Therapeutics Stock Is Crashing Today
The company reported disappointing results from a phase 2b clinical study.
Why Seres Therapeutics Stock Surged Today
A major investor boosted its stake in the microbiome therapeutics leader.
Why Seres Therapeutics Stock Skyrocketed 350% Today
The company's new dug could be a game changer.
Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.
The potential is significant. Unfortunately, so is the hype.
Here's Why Seres Therapeutics Stock Soared Today
A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.